Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.33 USD | -3.62% | -7.54% | -40.66% |
Financials (USD)
Sales 2024 * | 227M | Sales 2025 * | 282M | Capitalization | 789M |
---|---|---|---|---|---|
Net income 2024 * | 9M | Net income 2025 * | 71M | EV / Sales 2024 * | 1.73 x |
Net cash position 2024 * | 395M | Net cash position 2025 * | 448M | EV / Sales 2025 * | 1.21 x |
P/E ratio 2024 * |
95.3
x | P/E ratio 2025 * |
11.7
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.91% |
Latest transcript on Aurinia Pharmaceuticals Inc.
1 day | -3.62% | ||
1 week | -7.54% | ||
Current month | +4.81% | ||
1 month | +4.81% | ||
3 months | -10.34% | ||
6 months | -41.82% | ||
Current year | -40.66% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | -.--% | - | |
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 5.335 | -3.53% | 228 072 |
24-05-22 | 5.53 | -1.07% | 889,815 |
24-05-21 | 5.59 | -3.29% | 1,392,676 |
24-05-20 | 5.78 | +0.35% | 2,414,171 |
24-05-17 | 5.76 | -0.17% | 2,333,017 |
Delayed Quote Nasdaq, May 23, 2024 at 10:36 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.66% | 789M | |
+10.59% | 115B | |
+12.53% | 106B | |
-4.83% | 24.69B | |
-1.89% | 21.97B | |
-5.29% | 19.27B | |
-11.37% | 17.56B | |
-39.36% | 17.32B | |
+6.01% | 14.03B | |
+32.68% | 12.13B |
- Stock Market
- Equities
- AUPH Stock